Includes bibliographical references (p. 303-324).
|Other titles||Study of the patentability of proteins and DNA sequences with special emphasis on the disclosure requirement|
|Statement||Sven J.R. Bostyn.|
|Series||Eposcript -- v. 4|
|Contributions||European Patent Office.|
|The Physical Object|
|Pagination||xiv, 337 p. ;|
|Number of Pages||337|
Book Review. Reviewing Sven J.R. Bostyn, Enabling Biotechnological Inventions in Europe and the United States. Vol. 4 in the series. 33 INTERNATIONAL REV. INDUSTRIAL PROP. & COPYRIGHT L (). S.J.R. BOSTYN, Enabling Biotechnological Inventions in Europe and theUnited States: a study of the patentability of proteins and DNA sequences withspecial emphasis on the disclosure requirement, European Patent Office, A) Most relevant provisions regarding biotechnological inventions 1) Europe: European Patent Convention Art. , 83, 84; Rules 23 b-e, 28 and Directive 98/44/EC 2) US: Title 35 United States Constitution Section , , (c) B) Prerequisites of patentable subject matter For a living thing to be patentable, it must meet two File Size: KB. Buy Enabling biotechnological inventions in Europe and the United States: A study of the patentability of proteins and DNA sequences with special emphasis on the disclosure requirement (EPOscript) by Bostyn, Sven J. R (ISBN:) from Amazon's Book Store. Everyday low prices and free delivery on eligible : Sven J. R Bostyn.
This book analyses the forms and limitations of patent protection recognition for biotechnological inventions, with particular regard to patentability of life. The author expertly compares the United States model, traditionally based on technical evaluations, with the European model, inspired by fundamental rights and : Patenting biotechnological inventions Proteins and nucleic acids The patentability of proteins and DNA/RNA is assessed by the Patent Offices in the same way as any other chemical entities. If they are claimed in isolated or purified form, then that form will be novel over the forms that are present in the organism from which they are obtained. Patentability of biotechnological inventions I. EPO and patentability of inventions II. Focus on EPO 2. European Patent Office EPO Member States European Patent Organisation Founded in Some million inhabitants European member states (38) European extension states Bosnia and HerzegovinaFile Size: KB. Sven is the single author of more than 60 scientific publications. amongst which: ‘Enabling Biotechnological Inventions in Europe and the United States. A study of the patentability of proteins and DNA sequences with special emphasis on the disclosure requirement, Eposcript Series, nr. 4, EPO, München, , + pp.;.
"Conclusions: Biotechnological inventions and the patentability of living beings in the United States and European models between legal issues and bioethical profiles – The utility of the comparative method, the perspective of the legal process and relations with other sciences and humanistic disciplines (in particular bioethics)" published on 29 May by Edward Elgar : Andrea Stazi. Margaret Llewelyn, University of Sheffield, UK 'Biotechnological Inventions: Moral Restraints and Patent Law provides a roadmap for future research in the area of modern patent law. In this insightful, thought-provoking and thorough book, Mills provides a useful and timely introduction to the way that moral issues impinge on patents in Europe. requires Member States to protect biotechnological inventions (Article 1) and declares that inventions which satisfy the criteria for patentability shall be patentable even if they concern a product consisting of biological material (as defined in Article 2) or a procedure whereby biological material is produced. 1. The Importance of Follow-On Pharmaceutical Innovation. As indicated above, the Guidelines regard a broad variety of follow-on pharmaceutical innovation categories as being unworthy of patent protection. According to the Guidelines, these include: “selection patent” inventions; polymorphs; isolated enantiomers when the racemic mixture was previously disclosed; salts with advantageous Author: Christopher M. Holman, Timo Minssen, Eric M. Solovy.